Join Us | Latest Articles | Contact

Journal Home


Editorial Board


Recent Articles


Submit to this journal


Special Issues


Current issue

International Journal of Pathology and Clinical Research





DOI: 10.23937/2469-5807/1510009



Factors Predicting Response to Neoadjuvant Therapy of Hepatic Metastasis from Colorectal Carcinoma

D. Cortés Guiral, MJ Fernández-Aceñero*, D. García-Olmo and C. Pastor Idoate


Departments of Surgery, Surgical Pathology, Fundación Jiménez Díaz, Hospital Clínico San Carlos, Madrid, Spain


*Corresponding author: Dr. MJ Fernández-Aceñero, Departament of Surgical Pathology. Hospital Clínico San Carlos C/ Profesor Martín Lagos s/n 28040 Madrid, Spain, E-mail: mgg10167@gmail.com
Int J Pathol Clin Res, IJPCR-1-009, (Volume 1, Issue 1), Review Article; ISSN: 2469-5807
Received: August 14, 2015 | Accepted: August 31, 2015 | Published: September 03, 2015
Citation: Cortés Guiral D, Fernández-Aceñero MJ, García-Olmo D, Pastor Idoate (2015) Factors Predicting Response to Neoadjuvant Therapy of Hepatic Metastasis from Colorectal Carcinoma. Int J Pathol Clin Res 1:009. 10.23937/2469-5807/1510009
Copyright: © 2015 Guiral DC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Summary

Introduction: Neoadjuvant chemotherapy (NAC) is a widely used therapeutic option for patients with resectable hepatic metastasis from colorectal carcinoma. In this setting, the intent of NAC is to reduce metastatic size and make surgery easier and/or less extensive, mostly in patients that are amenable to surgery. Several studies confirm that response to neoadjuvant therapy is indicative of a better prognosis for such patients and several methods have been proposed and validated to measure both radiological and histopathological response. However, surgery remains the only curative option for these patients and patients should be operated on after chemotherapy regardless of response. Knowing this, it would be beneficial to predict which patients are likely to respond to therapy, for a lack of response could make resection of hepatic metastatic disease more difficult or even impossible and result in a delay in efficient therapy with negative consequences for the patient. Very few studies have analyzed this issue to date. The objective of the present study is to determine the factors that can predict response to NAC of hepatic metastasis from colorectal primary turmors.

Material and Methods: We reviewed the files of patients with colorectal carcinoma that developed hepatic metastasis and who received neoadjuvant chemotherapy before surgical resection of metastasis. We also gathered demographic, analytical and morphological data of the cases and reviewed the hepatic resection samples to measure the pathological response to chemotherapy according to Rubbia-Brandt et al. criteria. A statistical analysis was done to define which factors can help predict response to therapy.

Results: 50 patients fulfilled inclusion criteria for the present study. All of them had received a chemotherapeutic regimen mainly based on platinum, associated with or without targeted drugs (18% received anti-EGFR drugs and 24% anti-VEGFR drugs). Sixty-six% of the primaries were of sigmoid-rectal origin and 32% of the cases showed a good histopathological response to therapy (including 3 cases with a complete response). As for the factors predicting response to therapy, we performed a logistic regression analysis and found that only the histological differentiation of the primaries and the CEA levels prior to NAC, were statistically significant in association with histopathological response.

Discussion: At this moment it is not yet possible to predict precisely whether patients are going to respond or not to neoadyuvant therapy for hepatic metastasis from colorectal primaries. Overall, there is not a well established correlation between RECIST criteria of response and histopathological response, although morphological criteria rather than size shrinkage could potentially change this situation. Lack of response to neoadjuvant therapy could result in a delay in surgery, that could influence the prognosis of these patients and it is reasonable to predict which patients are more likely to respond to therapy. In our study, well differentiated primaries and also lower CEA levels prior to NAC predicted poor response. Nevertheless, larger studies are necessary to better resolve this question.


Keywords

Hepatic metastasis, Colorectal carcinoma, Neoadjuvant therapy, Prognosis, Histopathological response


Introduction

Colorectal carcinoma is one of the most frequent human malignancies, primarily in developed countries [1]. Despite recent advances in therapy, particularly after the introduction of targeted drugs against EGFR and VEGFR [2], mortality remains high for advanced stages, especially for metastatic disease. The best therapeutic option for metastasis amenable to resection is surgery and R0 resection is one of the most important prognostic factors in these patients [3]. Neoadjuvant chemotherapy (NAC) has been proposed as a therapeutic alternative for patients with metastatic disease in whom surgery is technically difficult [4]. In this sense, the objective of therapy is not to completely kill tumor cells, but rather to reduce tumor size and allow surgery [5]. However, some patients do not respond to NAC and some tumors may even progress during it. This can result in a delay in surgery or even make it impossible. For this reason it would be beneficial to know which patients are more likely to respond to therapy in this setting, a fact that has not been widely analyzed in the literature to date.


Material and Methods

We retrospectively reviewed the electronic files of the patients with colorectal carcinoma treated at the Fundación Jiménez Díaz Hospital in Madrid (Spain). From these we have included in the study those with initially resectable hepatic metastasis that received NAC and were subsequently operated on with disease free margins. After surgery they received standard adjuvant therapy. We have collected general demographic and clinical data and also data from the primary tumor (location, differentiation grade, vascular invasion, inflammatory response, TNM staging). We collected the CEA values before NAC. We also reviewed the stained slides of the metastatic hepatic nodules to describe the morphological response to therapy according to Rubbia-Brandt criteria [6]. We did not analyze radiological data of response, due to being inadequately reported in the clinical records of many patients.

We designed a data base in Excel and performed statistical analysis of the results with SPSS 20 for Windows statistical software (IBM corporation). We performed a descriptive analysis and a logistic regression model to find which factors can help predict response to therapy.

The permission for this study has been obtained from the Ethical Committee on Scientific Investigation of our hospital. This study is in accordance to national regulations regarding personal data protection.


Results

Inclusion criteria for the present study were met by 50 patients. Table 1 summarizes the general characteristics of the series. Table 2 summarizes the histopathological features of the primary colon tumors, according to their response. In our series, 3 patients showed a complete response (6%), 33 showed a minor response (66%) and 14 (28%) showed a major response.



Table 1: General characteristics of the 50 patients meeting inclusion criteria View Table 1



Table 2: Histopathological features of the primary tumors View Table 2


The statistical analysis of the factors influencing response was made considering both patients with complete and major response. We compared the mean values of the quantitative variables with Student's T test and estimated the association between qualitative variables with Chi-Square test. We only found significant differences in the mean values of CEA (p = 0.01), which were significantly higher in minor responders. For subsequent analysis we classified the patients in those with CEA values 5 ng/ml or less and those with CEA higher than 5 ng/ml, table 3 summarizes the data from this analysis.



Table 3: Univariate analysis: statistically significant associations View Table 3


Lastly, we performed a logistic regression model considering all the demographic and histopathological data that could influence response and found that only CEA preoperative levels (p = 0.02) significantly influenced response of the hepatic metastasis to NAC and histological differentiation of the tumor showed a trend toward significance (p = 0.07). Well differentiated tumors tended to respond less to NAC than poorly differentiated ones.


Discussion

NAC has emerged in recent times as a useful therapeutic approach to the management of hepatic metastasis from colorectal malignant tumors. It is well known that almost 50% of the patients with colon carcinoma will develop metastasis during follow-up and to improve survival it is essential to design aggressive therapeutic schemes that try to reduce the burden of disease and enhance response to adjuvant chemotherapy and also to targeted drugs [2]. Surgery of the metastasis is the best therapeutic alternative [3], but at times it may be difficult to achieve complete resection or surgery may be technically complex leading to some groups advocating the use of NAC to make resection more manageable.

NAC is usually based on oxaliplatin or irinotecan associated to fluoropyrimidines. Some schemes also employ targeted drugs (namely, anti-EGF and anti-VEGF drugs) in this setting. The response to therapy is usually followed with serial CT scans during NAC, for progression of disease could even make surgical resection impossible or recommend NAC cessation. However, it is rather clear than the RECIST criteria relying on size reduction are not well correlated to the histopathological response [7] and also that this criteria does not precisely predict prognosis after resection. In this sense radiologists have developed the so called morphological criteria [8,9], which seem to correlate better with histopathology and not only takes into account the shrinkage of the tumor, but rather also the changes in the radiological features of the metastatic nodules in the CT scan.

NAC combined with radiotherapy (NACRT) is a frequent therapeutic scheme for rectal tumours [10]. Pathological response to NACRT is one of the most important prognostic factors according to the literature in these patients. Schemes to evaluate response are varied [11], but most recent reports use the one recommended by the American College of Pathologists [12]. Over the years histopathological response to NAC of hepatic metastasis has also been evaluated with varying criteria. However, in 2008 Rubbia-Brandt proposed a new system to classify response creating three groups (complete, major and minor response), which showed good correlation with prognosis [6] and has been widely adopted. Rubbia-Brandt's criteria showed good correlation with morphological data of response in radiological follow-up and this is important for clinicians' decision making.

Besides, there are many reports trying to predict response of rectal carcinomas to therapy, for therapy is not devoid of adverse effects and it would be important to define patients that can benefit more from NAC [13]. Despite the many reports about the prognostic significance of histopathological response of metastasis, we have only found one previous report trying to predict response of the hepatic metastasis, as we intend to do in the present study [14]. In this report, Blazer et al. established that histopathological response of hepatic metastasis to NAC influenced prognosis (33% of patients with minor response were alive at 5 years follow-up as opposed to 75% of patients with major response), but also tried to determine which factors could influence response. In a multivariate analysis on 305 patients undergoing hepatic resection after NAC they concluded that CEA preoperative levels, tumor size and use of bevacizumab were significantly associated to histopathological major response. After this report, there have been no further ones specifically analyzing this issue. In our small series of 50 patients we have also tried to define which factors can significantly influence response to NAC. In the univariate analysis both CEA preoperative levels and differentiation of the primary tumor were significantly associated to major response, but in the multivariate logistic regression model, only CEA levels showed independent predictive value of response. Blazer's report does not mention the differentiation grade of the tumor in his analysis. Tumor size was not adequately reported in the clinical records of our patients and bevacizumab in our series was only administered in 11 patients (22%) not permitting conclusions to be obtained from these two factors.

Some reports have tried to determine the recurrence risk of patients with resected metastasis from colon carcinoma, even establishing predictive algorithms [15,16]. It would be beneficial to design similar algorithms for prediction of response to therapy with hopes to improve selection of the best candidates for this therapy as it is done in rectal carcinoma. In the near future molecular factors will probably gain interest in this area, as in many other oncologic fields [17].

The present study has several drawbacks, which deserve to be mentioned. The most important one is the small number of cases, although the results are similar to those obtained by Blazer [13] who had a much larger number of cases. Also, the retrospective nature has made it impossible to retrieve information regarding image data, mainly morphological changes in the nodules, which have become an interesting factor to predict response. It seems clear, however that prospective adequately powered studies are necessary to settle this matter and avoid NAC in patients less likely to respond, therefore reducing toxicity and allowing an earlier resection of the lesions if possible.


Acknowledgments

This work was partially funded with a grant of the Spanish Economy and Competitivity Ministry though the Program RETOS for 2014.


References
  1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.

  2. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767.

  3. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, et al. (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241: 715-72.

  4. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, et al. (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945.

  5. Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, et al. (2007) Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg 142: 269-276.

  6. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, et al. (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18: 299-304.

  7. Rothe JH, Grieser C, Lehmkuhl L, Schnapauff D, Fernandez CP, et al. (2013) Size determination and response assessment of liver metastases with computed tomography--comparison of RECIST and volumetric algorithms. Eur J Radiol 82: 1831-1839.

  8. Shindoh J, Loyer EM, Kopetz S et al. (2012) Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30: 4566-4572.

  9. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, et al. (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302: 2338-2344.

  10. Yoon WH, Kim HJ, Kim CH, Joo JK, Kim YJ, et al. (2015) Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer. Ann Surg Treat Res 88: 15-20.

  11. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, et al. (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73: 2680-2686.

  12. Mace AG, Pai RK, Stocchi L, Kalady MF (2015) American Joint Committee on Cancer and College of American Pathologists regression grade: a new prognostic factor in rectal cancer. Dis Colon Rectum 58: 32-44.

  13. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, et al. (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344-5351.

  14. Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, et al. (2009) Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 250: 582-589.

  15. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318.

  16. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, et al. (2007) Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 246: 806-814.

  17. Wanebo HJ, LeGolvan M, Paty PB, Saha S, Zuber M, et al. (2012) Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis 29: 821-839.

International Journal of Anesthetics and Anesthesiology (ISSN: 2377-4630)
International Journal of Blood Research and Disorders   (ISSN: 2469-5696)
International Journal of Brain Disorders and Treatment (ISSN: 2469-5866)
International Journal of Cancer and Clinical Research (ISSN: 2378-3419)
International Journal of Clinical Cardiology (ISSN: 2469-5696)
Journal of Clinical Gastroenterology and Treatment (ISSN: 2469-584X)
Clinical Medical Reviews and Case Reports (ISSN: 2378-3656)
Journal of Dermatology Research and Therapy (ISSN: 2469-5750)
International Journal of Diabetes and Clinical Research (ISSN: 2377-3634)
Journal of Family Medicine and Disease Prevention (ISSN: 2469-5793)
Journal of Genetics and Genome Research (ISSN: 2378-3648)
Journal of Geriatric Medicine and Gerontology (ISSN: 2469-5858)
International Journal of Immunology and Immunotherapy (ISSN: 2378-3672)
International Journal of Medical Nano Research (ISSN: 2378-3664)
International Journal of Neurology and Neurotherapy (ISSN: 2378-3001)
International Archives of Nursing and Health Care (ISSN: 2469-5823)
International Journal of Ophthalmology and Clinical Research (ISSN: 2378-346X)
International Journal of Oral and Dental Health (ISSN: 2469-5734)
International Journal of Pathology and Clinical Research (ISSN: 2469-5807)
International Journal of Pediatric Research (ISSN: 2469-5769)
International Journal of Respiratory and Pulmonary Medicine (ISSN: 2378-3516)
Journal of Rheumatic Diseases and Treatment (ISSN: 2469-5726)
International Journal of Sports and Exercise Medicine (ISSN: 2469-5718)
International Journal of Stem Cell Research & Therapy (ISSN: 2469-570X)
International Journal of Surgery Research and Practice (ISSN: 2378-3397)
Trauma Cases and Reviews (ISSN: 2469-5777)
International Archives of Urology and Complications (ISSN: 2469-5742)
International Journal of Virology and AIDS (ISSN: 2469-567X)
More Journals

Contact Us

ClinMed International Library | Science Resource Online LLC
3511 Silverside Road, Suite 105, Wilmington, DE 19810, USA
Email: contact@clinmedlib.org
 

Feedback

Get Email alerts
 
Creative Commons License
Open Access
by ClinMed International Library is licensed under a Creative Commons Attribution 4.0 International License based on a work at https://clinmedjournals.org/.
Copyright © 2017 ClinMed International Library. All Rights Reserved.